For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis (increases red blood cell levels) by the same mechanism as rHuEpo (binding and activating the Epo receptor) and is used to treat anemia, commonly associated with chronic renal failure and cancer chemotherapy.
Scope of the Report:
This report focuses on the Darbepoetin Alfa in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The classification of Darbepoetin Alfa includes Epogen, Procrit, Aranesp and others, and the proportion of Epogen in 2017 is about 45%.
Darbepoetin Alfa is widely used for Patients with Chronic Kidney Disease, Patients with Cancer others. The most proportion of Darbepoetin Alfa is used for the Patients with Chronic Kidney Disease, and the proportion in 2017 is 62%.
North America is the largest consumption place, with a consumption market share nearly 47% in 2017. Following North America, Europe is the second largest consumption place with the consumption market share of 41%.
The worldwide market for Darbepoetin Alfa is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Johnson & Johnson
- Kyowa Hakko Kirin
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Market Segment by Applications, can be divided into
- Patients with Chronic Kidney Disease
- Patients with Cancer
There are 15 Chapters to deeply display the global Darbepoetin Alfa market.
Chapter 1, to describe Darbepoetin Alfa Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Darbepoetin Alfa, with sales, revenue, and price of Darbepoetin Alfa, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Darbepoetin Alfa, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Darbepoetin Alfa market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Darbepoetin Alfa sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source